Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 2/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23827812 | 0.91 | CHRM1 (0.46) | CHRM1KCNH2ALOX5CYP2C9 | |
| SCHEMBL30211620 | 0.91 | CHRM1 (0.46) | CHRM1KCNH2ALOX5CYP2C9 | |
| SCHEMBL30211636 | 0.89 | CHRM1 (0.46) | CHRM1KCNH2ALOX5CYP2C9IRAK4 | |
| SCHEMBL20541813 | 0.89 | CHRM1 (0.46) | CHRM1KCNH2ALOX5CYP2C9IRAK4 | |
| SCHEMBL26360343 | 0.89 | CHRM1 (0.40) | CHRM1KCNH2ALOX5CYP2C9IRAK4 | |
| SCHEMBL26360576 | 0.88 | CHRM1 (0.40) | CHRM1KCNH2ALOX5CYP2C9IRAK4 | |
| SCHEMBL23827746 | 0.83 | CHRM1 (0.51) | CHRM1KCNH2ALOX5CYP2C9CYP11B1 | |
| SCHEMBL30211626 | 0.83 | CHRM1 (0.51) | CHRM1KCNH2ALOX5CYP2C9CYP11B1 | |
| SCHEMBL21654995 | 0.81 | CHRM1 (0.51) | CHRM1KCNH2ALOX5CYP2C9CYP11B1 | |
| SCHEMBL23827754 | 0.81 | CHRM1 (0.48) | CHRM1KCNH2ALOX5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303541-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303541-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | CHRM3, CHRNA1, CHRM5 | CHRM1 7/4885KCNH2 429/4885ALOX5 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.